Trial reportEuropean heart journal2024
Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial.
Trial report in European heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Evidence Map Analysis on Randomized Controlled Trials: Chinese Patent Medicines and Classic Traditional Chinese Medicine Prescriptions.Journal of evidence-based medicine · 2026Pooled it
- Efficacy and safety of acupuncture for arrythmias: an overview of systematic reviews and Meta-analyses.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Pooled it
- Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Clinical efficacy and mechanistic study of fulvning granules in symptomatic atrial fibrillation: a randomized controlled trial with untargeted metabolomics analysis.Frontiers in pharmacology · 2026Trial
- Effect of anti-anxiety therapy on the prognosis of patients with atrial fibrillation and anxiety: a 2 × 2 factorial randomized controlled trial.Frontiers in cardiovascular medicine · 2026Article
- Medicine-food homology substances in cardiovascular disease prevention and management: from mechanisms to clinical evidence and future translation.Frontiers in nutrition · 2026Review
- The mechanism of electrical remodeling in atrial fibrillation and current research status of natural drugs and active ingredients inhibiting atrial electrical remodeling.Frontiers in cardiovascular medicine · 2026Review
- Efficacy evaluation of Wenxin Keli in treating anthracycline-induced atrial arrhythmias (WARMA study): protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial.Frontiers in cardiovascular medicine · 2026Article
- Integrating Clinical Multi-Omics, Machine Learning, and Molecular Docking Strategies to Reveal the Mechanism of Yiqi Huoxue Prescription in the Treatment of Ischemic Heart Failure.Drug design, development and therapy · 2025Article
- The Shenlian Fumai Granule attenuates Ach-CaClFrontiers in cardiovascular medicine · 2025Article
- Traditional Chinese medicine: cardiovascular drug development through a holistic framework.European heart journal · 2024Article
- Traditional Chinese medicine for cardiovascular disease: efficacy and safety.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
BACKGROUND AND
aimsDespite advances in technology and techniques, the recurrence rate of persistent atrial fibrillation (AF) following catheter ablation remains high. The Shensong Yangxin (SSYX) capsule, a renowned traditional Chinese medicine formula, is used in the treatment of cardiac arrhythmias. This trial aimed to investigate whether the SSYX can improve clinical outcomes in patients who have undergone catheter ablation for persistent AF.
methodsA multi-centre, randomized, double-blind, placebo-controlled clinical trial was conducted at 66 centres in China among 920 patients with persistent AF undergoing first ablation. Participants were randomized to oral SSYX, 1.6 g (.4 g/granule) thrice daily (n = 460), or matched placebo (n = 460) for 12 months. The primary endpoint was recurrent atrial tachyarrhythmias lasting for ≥30 s following a blanking period of 3 months. Secondary endpoints included time to first documented atrial tachyarrhythmias, AF burden, cardioversion, stroke/systemic embolism, changes in echocardiographic parameters, and quality-of-life (QoL) score. Analyses were performed according to the intention-to-treat principle.
resultsA total of 920 patients underwent randomization (460 assigned to SSYX group and 460 assigned to placebo group). During the follow-up of 12 months, patients assigned to SSYX had a higher event-free rate from recurrent atrial tachyarrhythmias when compared with the placebo group (12-month Kaplan-Meier event-free rate estimates, 85.5% and 77.7%, respectively; hazard ratio, .6; 95% confidence interval .4-.8; P = .001). Patients assigned to receive SSYX had a better QoL score at 12 months compared to those randomized to placebo. There was no significant difference in the incidence of serious adverse events between the two groups.
conclusionsTreatment with SSYX following radiofrequency catheter ablation for persistent AF reduced the incidence of recurrent atrial tachyarrhythmias and led to clinically significant improvements in QoL during a 12-month follow-up in a Chinese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.